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Abstract
Background: Erythropoietin, through its specific receptor (EpoR), may induce responses in a variety of
non-haematopoietic tissues including malignant cells. The purpose of this study was to examine the
expression of EpoR in hepatocellular carcinoma (HCC) and to correlate the levels of EpoR expression with
the clinicopathological properties of HCC and tumour recurrence.
Methods: The study included 134 patients who underwent curative hepatectomy for hepatitis B virus
(HBV)-related primary HCC. The clinical, laboratory and pathological data from these patients were
retrospectively collected. The expression of EpoR mRNA and protein were evaluated by reverse
transcription-polymerase chain reaction (RT-PCR) and Western blot analysis, respectively.
Results: Expression of EpoR mRNA in the cirrhotic liver was positively correlated with tumour cell
differentiation and 1-year disease-free survival (74.8% in the high expression group versus 46.9% in the
low expression group; P = 0.001), as it was for EpoR mRNA expression in HCC (64.4% in the
high expression group versus 52.7% in the low expression group; P = 0.044). Tumour recurrence showed
stronger dependence on the expression of EpoR protein in non-malignant cirrhotic livers than in HCC.
Conclusion: In HBV-related HCC, the levels of EpoR mRNA and protein in non-tumour cirrhotic
livers were positively correlated with tumour cell differentiation, which is a favourable predictor of
disease-specific survival.
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Introduction
Erythropoietin (Epo) is a glycoprotein hormone with a central
regulatory role in red blood cell formation.1 A specific transmem-
brane erythropoietin receptor (EpoR) mediates the action of Epo
in several non-haematopoietic tissues including the heart, blood
vessels, kidneys and brain, suggesting that Epo/EpoR signalling
may influence functions other than erythropoiesis.2–4 Epo is now
known to mediate events in embryonic neural development, neo-
vascularization, the T-cell mediated immune response and wound
healing, and may protect the heart and kidneys from ischaemic
injury.5
Active Epo/EpoR signalling has been detected in carcinomas
of the breast,6–8 ovary,9 kidney,10 prostate,11 stomach,12
pancreas,12 lung,12 squamous tissues of the head and neck,13
and neuroblastoma.14 Evidence suggests that Epo may adversely
affect cancer patient survival by stimulating tumour cell prolifera-
tion, inhibiting apoptosis, inducing angiogenesis during tumour
growth, promoting survival of hypoxic cancer cells, inducing
tumour cell migration, and modulating tumour sensitivity to
chemoradiation therapy.1,15,16
Hepatocellular carcinoma (HCC) is one of the most highly
vascularized solid tumours, and angiogenesis plays a prominent
role in the development and progression of HCC.17 Accordingly,
the action of EpoR in HCC may have particular clinical signifi-
cance. This is an observational study which aimed to measure the
expression of EpoR mRNA and protein in tumour and non-
tumour liver tissue from patients with HCC using reverse
transcription-polymerase chain reaction (RT-PCR) and Western
blot analysis, and to retrospectively correlate these levels to the
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clinicopathological properties of the tumours and with tumour
recurrence.
Materials and methods
Patient population and tissue samples
From January 2006 to May 2010, the study included 134 patients
diagnosed with hepatitis B virus (HBV)-related primary HCC in
the Samsung Medical Center Department of Surgery. All patients
included this study had sera positive for HBsAg, implying chronic
hepatitis B infection, and underwent acurative hepatectomy with
a negative resection margin. Only the patients who agreed with
the universal informed consents for their specimens to be used in
the experiments were included. Patients who had had a previous
hepatectomy or neoadjuvant treatments such as transarterial
chemoembolization, radiofrequency ablation or portal vein
embolization were excluded. One patient with hepatitis C virus
co-infection was also excluded. As a prior ischaemic insult to the
liver or previous viral infection could affect the histology of liver
tissue and biology of the EpoR expression, patients with a history
of this were excluded. Immediately after the complete resection of
pathological lesions, tissue samples were obtained from both the
non-tumour cirrhotic liver (N) and the HCC (T). One-half of
each sample was processed for histopathological examination and
the other half was stored at -70°C until RNA was extracted.
RT-PCR
The expression of EpoR mRNA in the non-tumour cirrhotic liver
tissue and the HCC were determined using RT-PCR. Total RNA
was isolated from tissues with an RNA preparation kit (Hybrid-R,
GeneAll Biotechnology Co., Ltd, Seoul, Korea) and quantified
using a Nano-Drop cuvette-free spectrophotometer (NanoDrop
Technologies, Inc., Wilmington, DE, USA). For synthesis of
cDNA, 2 mg of each total RNA sample was used as a template.
Single-stranded cDNA was prepared using AMV reverse tran-
scriptase with oligo-dT primers (Intron Biotechnology, Seoul,
Korea) and amplified for PCR using Pfu Taq polymerase (Solgent
Co. Ltd, Daejeon, Korea). The primers used for EpoR amplifica-
tion were the following: EpoR (550bp) forward 5′-cgg gga cag atg
atg agg-3′, reverse 5′-gca gcc tgg tgt cct aag ag-3′; GAPDH (200bp)
forward 5′-TCC TGC ACC ACC AAC TGC TT-3′, reverse 5′-TCC
ACC ACC CTG TTG CTG TA-3′. PCR products were separated
by electrophoresis on 1.5% agarose gel, visualized by ethidium
bromide staining and quantified using Quantity One software
(Bio-Rad, Hercules, CA, USA). As there is no absolute quantifica-
tion method to analyse data from RT-PCR, the values of EpoR
mRNA were expressed as a relative quantification by dividing the
values of GAPDH.
Western blot analysis
Tissues or cells were lysed with RIPA lysis buffer (Intron, Seoul,
South Korea) containing protease inhibitor (Thermo Fisher Sci-
entific, Inc., Rockford, IL, USA) to isolate the whole protein. The
protein concentration was quantified using a BCA protein assay
kit (Thermo Fisher Scientific, Inc.). Equal amounts of extracted
protein (50 mg) were loaded into each lane of a 10% sodium
dodecyl sulfate polyacrylamide electrophoresis gel. After electro-
phoresis, proteins were transferred to a polyvinylidenedifluoride
membrane filter (Millipore, Billerica, MA, USA) which had been
soaked in blocking buffer (4% skim milk) for 60 min and then
incubated overnight with rabbit anti-human EpoR polyclonal
antibody 1:200 (Santa Cruz Biotechnology, Inc., Santa Cruz, CA,
USA). To quantify the total protein, mouse anti-human b-actin
polyclonal antibody 1:4000 (Sigma Aldrich Co., St. Louis, MO,
USA) was included. The blot was incubated for 1 h with either
horseradish peroxidase (HRP)-conjugated anti-mouse IgG 1:1000
or HRP-conjugated anti-rabbit IgG 1:1000 (TrueBlot, eBioscience,
San Diego, CA, USA). Proteins stained with an enhanced chemi-
luminescence kit (AbFrontier, Seoul, South Korea) were exposed
to X-ray film (Agfa, Bonn, Germany). The level of protein expres-
sion was measured using Image J software (Version 1.43; National
Institutes of Health, Bethesda,MD,USA). Relative protein expres-
sion was quantified by normalization to b-actin. The expression of
EpoR protein was analysed in both cirrhotic tissue andHCC using
Western blots. A total of 119 paired data were collected.
Control group
To obtain the baseline values of the EpoR expression in human
liver tissue, 40 samples of normal liver tissue without cirrhosis or
HCC were collected for the control group. The values of EpoR
mRNA and protein in these hepatic tissues were measured. The
mean intensity value (INT) of EpoR mRNA expression was 0.812
 0.257 (median, 0.832; range, 0.338~1.220) INT.Using this value
as a cut-off point, the patient population were divided into two
groups: a high EpoR mRNA expression group and a low EpoR
mRNA expression group. The mean intensity value of EpoR
protein expression was 2.271  6.297 (median, 0.817; range,
0.036~36.703) OD. Here, OD is the unit of log10 (255/pixel value).
For the analysis of EpoR mRNA expression, a high EpoR protein
expression group and a low EpoR protein expression group were
also defined.
Clinical, laboratory and pathological data
Post-operatively, the patients were seen every 2 weeks during the
first month, and then once every 3 months. The clinical records of
the 134 patients included in the study were retrospectively
reviewed. Pre-operative laboratory results including haemo-
globin, liver function tests, tumour markers and serological viral
titres were recorded. Pathological data included tumour size, mul-
tiplicity, gross type, growth pattern, cell type, microvascular inva-
sion and degree of tumour differentiation (Edmonson grade). The
p53, cyclin D1 and cyclin E expression in HCC tissues were ana-
lysed by immunohistochemical staining.
Statistical analysis
All data were expressed as means standard deviations and ana-
lysed using SPSS version 18.0 (SPSS Inc., Chicago, IL, USA). Cat-
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egorical variables were analysed by Pearson’s chi-square test or
Fisher’s exact test, and continuous data by Spearman’s rank cor-
relation. Disease-specific and overall-survival rates were com-
puted using the Kaplan–Meier method. Differences in survival
were calculated using the log-rank test. In all of the tests used,
P-values less than 0.05 were considered statistically significant.
Results
The study population included 131 patients who were classified as
Child A in Child–Turcotte–Pugh classification (97.8%) and 3
patients as Child B (2.2%). None of the patients had a history of
portal hypertensive complications such as uncontrolled ascites or
hepatic encephalopathy. The mean value of the indocyanine green
test to estimate the remaining liver function was 9.64  5.53%.
The mean follow-up period after a hepatectomy was 683  384
days. During the study period, 69 patients (51.5%) experienced
disease recurrence and 37 died (27.6%). The mean disease-free
time and mean overall survival time of the patients were 523.2 
421.1 and 802.3 390.6 days, respectively. Patients with recurrent
HCC were treated with a repeat hepatectomy or transarterial
chemoembolization if they were not surgical candidates.
Expression of EpoR mRNA in non-tumour cirrhotic
liver tissue: EpoR-R (N)
Correlations of EpoR-R (N) expression with laboratory and clin-
icopathological data are presented in Table 1A. The mean inten-
sity value of EpoR mRNA expression in non-tumour cirrhotic
liver tissue [EpoR-R (N)] was 0.709  0.489 (median, 0.600;
range, 0.009~3.917) INT. Specifically, a high level of EpoR-R (N)
expression was more frequently in conjunction with well-
differentiated HCC (Edmonson grade 1) than with poorly differ-
entiated tumours (grade 3). In Fig. 1a, Kaplan–Meier survival
curves show a significantly longer disease-free survival in patients
with high EpoR-R (N) expression than in those with low EpoR-R
(N) expression. Overall survival did not differ according to
EpoR-R (N) expression.
Expression of EpoR mRNA in hepatocellular
carcinoma tissue: EpoR-R (T)
Correlations of EpoR-R (T) expression with laboratory and clin-
icopathological data are presented in Table 1B. Analysis of EpoR
mRNA in HCC tissue [EpoR-R (T)] by RT-PCR produced an
expression value of 0.622  0.376 (median, 0.542; range,
0.033~2.044) INT. Survival data by degree of EpoR-R (T) expres-
sion is shown in Fig. 1b.
Correlation between EpoR-R (N) and EpoR-R (T)
A close relationship was identified in this series of patients
between the EpoR-R (N) and EpoR-R (T) as shown in Fig. 2.
However, although the correlation of EpoR-R (N) and EpoR-R
(T) between groups was obvious, the same correlation did not
hold within individuals, i.e. the intensity of EpoR-R (T) expres-
sion did not always correspond to the intensity of EpoR-R (N)
expression in tissue samples from the same patient. In 79 patients
(59.0%), the intensity of EpoR-R (T) expression was lower than
EpoR-R (N) expression in non-malignant cirrhotic tissue sur-
rounding the tumour. The other 55 patients (41.0%) had higher
values for EpoR-R (T) expression than for EpoR-R (N); in other
words, a ratio of EpoR-R (T/N) expression greater than 1.
Significance of EpoR-R expression in patients
with HCC
The clinicopathological variables were compared for four patient
groups categorized by the relative degrees of EpoR-R expression in
non-malignant cirrhotic liver and HCC. The number of patients
with both high EpoR-R (N) and high EpoR-R (T); high EpoR-R
(N) and low EpoR-R (T); low EpoR-R (N) and high EpoR-R (T);
and low EpoR-R (N) and low EpoR-R (T) was 42 (31.3%), 12
(9.0%), 16 (11.9%) and 64 (47.8%), respectively. In statistical
analysis of clinicopathological variables, group categorization was
only significantly associated with the degree of tumour cell differ-
entiation (P = 0.002, data not shown). Survival analysis for the
four groups in relation to EpoR-R expression (Fig. 3) showed that
the group with both high EpoR-R (N) and high EpoR-R (T) had
the longest disease-free survival.
Significance of EpoR protein expression in cirrhotic
liver and hepatocellular carcinoma: EpoR-P (N)
and EpoR-P (T)
The mean values were 1.417  1.801 (median, 0.813; range,
0.037~11.097) OD and 1.948  4.156 (median, 0.879; range,
0.058~33.486) OD, respectively. The correlation between EpoR-P
expression and laboratory or clinicopathological features are
shown in Table 2. Survival data are shown in Fig. 4.
Discussion
Kayser and Gabius18 first suggested that human tumours might
express EpoR and subsequent studies confirmed the presence of
EpoR in different types of cancers. Sereno et al.19 suggested that
patterns of EpoR expression may be related to disease-free sur-
vival in patients with cancer, specifically in patients with gastric
adenocarcinoma.
This study demonstrated the expression of EpoR protein and
mRNA in cirrhotic liver tissue as well as in associated HCC iden-
tified a positive correlation between EpoR expression in either
cirrhotic liver or HCC and disease-free survival. In addition, this
study showed that the expression of EpoR protein in cirrhotic liver
tissue rather than HCC itself was negatively related to tumour
recurrence. EpoR protein appeared to be more important in the
non-malignant cirrhotic liver than in the tumour.
In erythroid progenitor cells, Epo induces cell differentiation in
a stage-specific manner.10 Likewise, in the present study, EpoR
expression was significantly greater in HCC that displayed a low
histological grade. In breast and gastric cancer, Acs et al.7 and
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Ribatti et al.20 reported that EpoR expression depends strongly on
cancer grade. Chabowska et al.21 also demonstrated that EpoR
expression is significantly higher in moderately-differentiated
colorectal cancers than in less differentiated cancers. They sug-
gested that the better histological differentiation may result from
improved supply of oxygen and the trophic influence of Epo and
EpoR.21 Sereno et al.19 suggested that well-differentiated tumours
had better preserved protein synthetic machinery than less well-
differentiated tumours and that higher EpoR expression was a
consequence rather than a cause of the differentiated state. The
findings of this study suggested that HCC with more highly-
differentiated cells produced higher levels of EpoR protein and
that the degree of tumour cell differentiation was positively
related to disease-free survival in patients with HCC. In other
words, the better histological level of tumour cell differentiation in
HCC resulted from the improved oxygen supply because of the
high level of EpoR protein expression in the background cirrhotic
liver before the development of HCC, at the same time, which is a
favourable factor in disease-free survival of the patients with
HCC.
Table 1 Statistical significance of erythropoietin receptor mRNA (EpoR-R) expression in non-tumour cirrhotic liver (A) and hepatocellular
carcinoma (HCC) (B) according to pre-operative laboratory data and clinicopathological features of HCC
Variables (A) EpoR-R expression in
non-tumour cirrhotic liver
(B) EpoR-R expression in HCC
Low EpoR-R
(n = 80)
High EpoR-R
(n = 54)
P-value Low EpoR-R
(n = 76)
High EpoR-R
(n = 58)
P-value
Patient age (years) 49.3  9.5 50.7  7.2 0.713 50.4  9.6 49.1  7.2 0.466
Patient gender: male 67 (83.8) 43 (79.6) 0.542 63 (82.9) 47 (81.0) 0.781
Child–Turcotte–Pugh (CTP) score 5.3  0.5 5.2  0.6 0.628 5.2  0.4 5.3  0.7 0.559
Pre-operative laboratory findings
Haemoglobin (g/dl) 14.5  1.7 14.6  1.7 0.796 14.7  1.6 14.3  1.7 0.304
Albumin (g/dl) 4.0  0.5 4.0  0.6 0.714 4.1  0.4 3.9  0.6 0.208
Total bilirubin (mg/dl) 0.8  0.4 0.7  0.3 0.442 0.8  0.4 0.7  0.4 0.067
Aspartate aminotransferase (U/l) 50.3  39.1 47.4  36.5 0.634 50.3  39.0 47.7  36.9 0.632
Alanine aminotransferase (U/l) 59.7  77.3 55.3  44.7 0.881 53.3  56.4 62.0  77.0 0.827
Alkaline phosphatase (U/l) 86.7  32.5 95.6  68.5 0.474 88.6  32.9 92.5  66.6 0.254
Prothrombin time (INR) 1.07  0.09 1.09  0.12 0.662 1.07  0.08 1.09  0.12 0.274
Tumour marker
Alpha-fetoprotein (¥104 ng/ml) 3.0  2.3 1.6  4.3 0.748 3.1  2.3 1.5  4.2 0.789
PIVKA-IIa (ng/ml) 274.0  222.3 172.8  217.3 0.123 239.7  220.6 245.9  234.3 0.871
Serological viral titre
HBV DNA titer (IU) 36.0  132.6 18.8  54.7 0.802 23.0  68.7 40.3  154.6 0.343
Post-operative pathology findings
Tumour size (cm) 6.1  3.3 5.4  2.8 0.011 6.0  3.3 5.5  3.0 0.093
Multiplicity: multiple 8 (10.0) 4 (7.4) 0.762 6 (7.9) 6 (10.3) 0.623
Perinodular extension 64 (80.0) 41 (75.9) 0.232 61 (80.3) 44 (75.9) 0.639
Microtrabecular pattern 65 (81.3) 42 (77.8) 0.677 61 (80.3) 46 (79.3) 0.720
Classic cell type 62 (77.5) 47 (87.0) 0.206 58 (76.3) 51 (87.9) 0.160
Differentiation
Edmonson grade 1 1 (1.3) 16 (29.6) 0.001 2 (2.6) 15 (25.9) 0.033
Edmonson grade 2 67 (83.8) 27 (50.0) 60 (78.9) 34 (58.6)
Edmonson grade 3 12 (15.0) 11 (20.4) 14 (18.4) 9 (15.5)
Microvascular invasion 59 (73.8) 36 (66.7) 0.376 54 (71.1) 41 (70.7) 0.963
Immunohistochemical staining
p53: positive 20 (25.0) 30 (55.6) 0.001 20 (26.3) 30 (51.7) 0.006
Cyclin D1: positive 25 (31.3) 19 (35.2) 0.865 23 (30.3) 21 (36.2) 0.749
Cyclin E: positive 25 (31.3) 18 (33.3) 0.954 22 (28.9) 21 (36.2) 0.616
All data were presented as number (%) or mean value  standard deviation.
aPIVKA-II, des-r-carboxyprothrombin.
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Several recent studies7,21–24 have reported significant over-
expression of EpoR in malignant tumour cells compared with
normal or benign adjacent tissue.However, the relationship found
here between EpoR expression in cirrhotic livers and EpoR
expression in HCC was not consistent with these previous obser-
vations. Although EpoR (T/N) expression differed significantly
between groups, it was impossible to establish a similar correla-
tion within individuals. In only 59.0% of patients in this group
was EpoR expression in HCC higher than that in adjacent cir-
rhotic liver tissue. In concordance with the findings of this study,
Feldman et al. and Sinclair et al. found no increase in tumour
levels of EpoR transcripts relative to normal tissues in renal cell
carcinoma,25 melanoma,25 or prostate cancer.11
It is widely accepted that the hypoxic core environment in some
solid tumours may induce EpoR expression,6,22 as a function
of hypoxia-inducible factor-1 regulation.1,26–30 Mohyeldin et al.13
observed that EpoR expression levels are highest in hypoxic
tumour regions. Other investigators measured increased EpoR
(a)
Figure 1 Disease-free survival and overall survival of hepatocellular carcinoma (HCC) patients according to the erythropoietin specific
receptor (EpoR) mRNA expression in non-malignant cirrhotic liver and hepatocellular carcinoma
(a) Survival according to EpoR mRNA in non-tumour cirrhotic liver
Disease-free survival rate Overall survival rate
(Number at risk) (Number at risk)
6 months 1 year 2 years 6 months 1 year 2 years
Low EpoR-R (N) group (n = 80; 59.7%) 63.5% 46.9% 36.7% 98.8% 85.9% 70.0%
(50) (34) (20) (79) (66) (44)
High EpoR-R (N) group (n = 54; 40.3%) 83.1% 74.8% 66.3% 98.1% 90.5% 82.6%
(43) (35) (22) (53) (47) (41)
(b) Survival according to EpoR mRNA in hepatocellular carcinoma
Disease-free survival rate Overall survival rate
(Number at risk) (Number at risk)
6 months 1 year 2 years 6 months 1 year 2 years
Low EpoR-R (T) group (n = 76; 56.7%) 69.4% 52.7% 37.7% 98.7% 87.6% 71.7%
(51) (37) (16) (75) (62) (41)
High EpoR-R (T) group (n = 58; 43.3%) 75.7% 64.4% 58.3% 98.3% 87.9% 79.0%
(43) (34) (26) (57) (51) (43)
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(b)
Figure 1 Continued.
Figure 2 Linear correlation between the intensity of the erythropoietin specific receptor (EpoR) mRNA expression in non-tumour cirrhotic liver
and hepatocellular carcinoma (HCC)
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mRNA levels in breast cancer cells immediately after hypoxia
exposure.6,31 However, based on the findings of this study,
it is suggested that a hypervascularized solid tumour such as
HCC would probably not up-regulate EpoR expression by the
tissue hypoxia pathway. Vascular changes within the HCC are
characterized by arterialization and sinusoidal capillarization,17
which do not promote hypoxia. This may explain why EpoR (T)
expression did not consistently exceed the level of EpoR (N)
expression.
Studies show that EpoR protein expression in cancer cells may
contribute to disease progression or invasiveness through the anti-
apoptotic and pro-migratory effects of Epo;10,13,16,32 however, other
studies contradict these findings. Westphal et al.33 and Farrell and
Lee34 demonstrated that Epo does not increase the proliferation
rate of EpoR-positive cells in malignant and benign human cell
lines. Similar studies show that tumour cell growth does not
depend critically on EpoR expression.21,35
In a murine myeloma model, Mittelman et al.36 found that Epo
induces tumour regression by promoting an effective antitumour
immune response. Carvalho et al.37 suggested that, at least in a
specific subset of renal cell carcinomas, an EpoR agonist may
enhance the propensity of EpoR-positive tumour cells to undergo
apoptosis. Pinto et al.38 reported that Epo mediates the expression
of hepcidin, the principal iron regulatory hormone, in hepato-
cytes. Thus Epo may promote terminal differentiation as opposed
to proliferation and tumour progression in these cells.
Figure 3 Survival in hepatocellular carcinoma (HCC) patient groups classified by the relative erythropoietin specific receptor EpoR mRNA
expression in non-tumour cirrhotic liver and HCC
Disease-free survival rate Overall survival rate
(Number at risk) (Number at risk)
6 months 1 year 2 years 6 months 1 year 2 years
High EpoR-R (N) and high EpoR-R (T) 78.2% 72.8% 63.9% 97.6% 88.1% 80.9%
(n = 42; 31.3%) (31) (27) (19) (41) (37) (33)
High EpoR-R (N) and low EpoR-R (T) 91.7% 81.5% 57.0% – 88.9% 87.8%
(n = 12; 9.0%) (11) (8) (4) (12) (8) (6)
Low EpoR-R (N) and high EpoR-R (T) 62.5% 43.8% 37.5% – 87.5% 75.0%
(n = 16; 11.9%) (10) (7) (6) (16) (14) (12)
Low EpoR-R (N) and low EpoR-R (T) 65.4% 54.2% 34.3% 98.4% 85.5% 68.8%
(n = 64; 47.8%) (41) (34) (13) (63) (52) (34)
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As indicated above, Epo-EpoR signalling may be detected in
several tumour types and may promote tumour progression by
different mechanisms, especially in highly vascularized tumour
types. Therefore, it was relevant to test the role of Epo-EpoR
signaling in HCC. The findings of this study revealed that EpoR
mRNA and protein were found in both non-tumour and HCC
liver samples and EpoR expression in both tissues was correlated
with disease-free survival. It also explained why EpoR expression
in HCC did not exceed EpoR expression in non-tumour liver
tissue, as HCC generally does not have a central hypoxia as other
tumour types. The most interesting finding in this study is the
presence of EpoR in non-tumour liver tissue and its correlation
with less-differentiated HCC and with decreased survival, prob-
ably because the expression of growth-regulatory cell surface
receptors corresponds to a higher degree of tumour cell differen-
tiation and therefore to a lower tumour grade. This finding may
suggest the use of a non-tumour liver biopsy with EpoR expres-
sion quantification prior to HCC treatment in order to define the
optimal therapeutic approach, depending on the probability of
intra-hepatic tumour recurrence. In fact, there is currently a
Table 2 Functional significance of erythropoietin receptor protein (EpoR-P) expression in non-tumour cirrhotic liver (A) and hepatocellular
carcinoma (HCC) (B) according to pre-operative laboratory data and clinicopathological features of HCC
Variables (A) EpoR-P expression in
non-tumour cirrhotic liver
(B) EpoR-P expression in
hepatocellular carcinoma
Low EpoR-P
(n = 91)
High EpoR-P
(n = 28)
P-value Low EpoR-P
(n = 92)
High EpoR-P
(n = 27)
P-value
Patient age (years) 49.7  8.8 49.9  8.8 0.159 49.5  9.0 50.6  8.4 0.678
Patient gender: male 77 (84.6) 24 (85.7) 0.871 78 (84.8) 23 (85.2) 0.807
Child–Turcotte–Pugh (CTP) score 5.1  0.4 5.4  0.5 0.422 5.1  0.3 5.4  0.7 0.168
Pre-operative laboratory findings
Haemoglobin (g/dl) 14.6  1.6 14.7  1.5 0.271 14.6  1.6 14.3  1.4 0.675
Albumin (g/dl) 4.1  0.4 3.9  0.5 0.121 4.1  0.4 3.8  0.5 0.656
Total bilirubin (mg/dl) 0.7  0.3 0.9  0.5 0.441 0.7  0.3 0.8  0.3 0.081
Aspartate aminotransferase (U/l) 50.4  37.5 46.7  15.6 0.952 49.4  38.8 51.2  17.6 0.560
Alanine aminotransferase (U/l) 61.0  64.2 43.9  20.9 0.907 61.7  67.0 47.0  20.2 0.559
Alkaline phosphatase (U/l) 92.6  54.6 85.1  33.4 0.680 87.8  32.7 104.0  90.9 0.954
Prothrombin time (INR) 1.07  0.10 1.08  0.08 0.881 1.06  0.08 1.12  0.14 0.448
Tumour marker
Alpha-fetoprotein (¥104 ng/ml) 2.7  1.7 1.1  4.7 0.961 2.9  1.7 0.8  3.9 0.851
PIVKA-IIa (ng/ml) 250.4  224.8 272.9  212.8 0.192 229.3  222.9 332.1  202.3 0.248
Serological viral titre
HBV DNA titer (IU) 41.3  134.4 53.0  83.7 0.790 35.6  132.7 27.9  68.7 0.538
Post-operative pathology findings
Tumour size (cm) 5.8  3.2 6.5  3.5 0.438 5.8  3.0 6.5  3.8 0.976
Multiplicity: multiple 7 (7.7) 2 (7.1) 0.692 6 (6.5) 2 (7.4) 0.904
Perinodular extension 78 (85.7) 24 (85.7) 0.542 77 (83.7) 25 (92.6) 0.501
Microtrabecular pattern 78 (85.7) 21 (75.0) 0.976 79 (85.9) 20 (74.1) 0.681
Classic cell type 67 (73.6) 27 (96.4) 0.245 74 (80.4) 21 (77.8) 0.825
Differentiation
Edmonson grade 1 6 (6.6) 11 (39.3) 0.002 6 (6.5) 1 (3.7) 0.080
Edmonson grade 2 67 (73.6) 15 (53.6) 80 (87.0) 22 (81.5)
Edmonson grade 3 18 (19.8) 2 (7.1) 6 (6.5) 4 (14.8)
Microvascular invasion 60 (65.9) 23 (82.1) 0.371 63 (68.5) 20 (74.1) 0.681
Immunohistochemical staining
p53: positive 19 (20.9) 5 (17.9) 0.098 27 (29.3) 7 (25.9) 0.313
Cyclin D1: positive 20 (22.0) 9 (32.1) 0.583 29 (31.5) 10 (37.0) 0.531
Cyclin E: positive 17 (18.7) 7 (25.0) 0.521 22 (23.9) 12 (44.4) 0.615
All data were presented as number (%) or mean value  standard deviation.
aPIVKA-II, des-r-carboxyprothrombin.
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crucial need to identify surrogate markers of tumour aggressive-
ness in HCC. The expression of Epo-R protein in the non-tumour
liver may prove to be a valuable tool in identifying patients at risk
of intra-hepatic recurrence and thus, to indicate liver transplan-
tation rather than a partial resection. Therefore, the results of this
study may be of particular importance in HCC management.
In conclusion, expression of EpoR mRNA was demonstrated in
both non-tumour cirrhotic liver and HCC. In the non-tumour
cirrhotic liver, EpoR mRNA expression was associated negatively
with tumour size and positively with the degree of differentiation
and p53-staining intensity. Expression of EpoR mRNA in HCC
was associated with tumour differentiation and p53 staining.
Expression of EpoR mRNA in either cirrhotic liver or HCC was
positively correlated with disease-free survival, and patients with a
high level of EpoR mRNA expression in both cirrhotic liver and
HCC had the longest disease-free survival. Tumour recurrence in
patients with HCC was related to the expression of EpoR protein
in non-malignant cirrhotic liver but not to the expression in HCC
(a)
Figure 4 Disease-free survival and overall survival of hepatocellular carcinoma (HCC) patients according to the erythropoietin specific
receptor (EpoR) protein expression in the cirrhotic liver and hepatocellular carcinoma as determined using Western blot analysis
(a) Survival according to EpoR protein in cirrhotic liver
Disease-free survival rate Overall survival rate
(Number at risk) (Number at risk)
6 months 1 year 2 years 6 months 1 year 2 years
Low EpoR-P (N) group (n = 91; 76.5%) 67.2% 45.8% 35.5% 98.5% 85.0% 74.9%
(44) (27) (17) (67) (56) (42)
High EpoR-P (N) group (n = 28; 23.5%) 74.1% 66.6% 53.9% 96.8% 89.3% 77.6%
(22) (18) (11) (27) (23) (18)
(b). Survival according to EpoR protein in HCC
Disease-free survival rate Overall survival rate
(Number at risk) (Number at risk)
6 months 1 year 2 years 6 months 1 year 2 years
Low EpoR-P (T) group (n=92; 77.3%) 69.4% 56.4% 44.2% 98.7% 86.5% 78.8%
(51) (38) (24) (75) (63) (47)
High EpoR-P (T) group (n=27; 22.7%) 59.3% 37.0% 30.8% 95.0% 85.0% 64.0%
(11) (6) (5) (19) (17) (12)
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itself. It is suggested that high levels of EpoR mRNA and protein
expression in HBV-related HCC correspond to high levels of
tumour cell differentiation and p53 expression, which are favour-
able markers in disease-free survival.
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